Metastatic Anaplastic Thyroid Cancer (DBCOND0040044)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Dabrafenib	A kinase inhibitor used to treat patients with specific types of melanoma, non-small cell lung cancer, and thyroid cancer.	Cytochrome P450 3A4enzyme Cytochrome P450 2C8enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Solute carrier organic anion transporter family member 1B1transporter Solute carrier organic anion transporter family member 1B3transporter Solute carrier family 22 member 6transporter Organic anion transporter 3transporter Serine/threonine-protein kinase B-raftarget RAF proto-oncogene serine/threonine-protein kinasetarget Serine/threonine-protein kinase SIK1target Serine/threonine-protein kinase Nek11target LIM domain kinase 1target Cytochrome P450 2B6enzyme Cytochrome P450 2C9enzyme Cytochrome P450 2C19enzyme Cytochrome P450 1A2enzyme Albumincarrier Solute carrier organic anion transporter family member 1A2transporter Solute carrier family 22 member 2transporter UDP-glucuronosyltransferase 1A1enzyme
Trametinib	A kinase inhibitor used alone or in combination with dabrafenib to treat patients with cancers with specific BRAF mutations, such as melanoma and non-small cell lung cancer.	Cytochrome P450 2C8enzyme Cytochrome P450 3A4enzyme Dual specificity mitogen-activated protein kinase kinase 1target Dual specificity mitogen-activated protein kinase kinase 2target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT03122496	Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer	Durvalumab Tremelimumab	treatment	1	completed
NCT02289144	Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer	Ceritinib	treatment	2	withdrawn
NCT00654238	Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer	Acetylsalicylic acid Sorafenib	treatment	2	completed